CN105705149A - 用于预防或治疗系统性红斑狼疮和/或狼疮性肾炎的方法 - Google Patents

用于预防或治疗系统性红斑狼疮和/或狼疮性肾炎的方法 Download PDF

Info

Publication number
CN105705149A
CN105705149A CN201480060987.4A CN201480060987A CN105705149A CN 105705149 A CN105705149 A CN 105705149A CN 201480060987 A CN201480060987 A CN 201480060987A CN 105705149 A CN105705149 A CN 105705149A
Authority
CN
China
Prior art keywords
compound
amino
lupus erythematosus
systemic lupus
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480060987.4A
Other languages
English (en)
Chinese (zh)
Inventor
河村透
藤谷靖志
泷泽正之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CN105705149A publication Critical patent/CN105705149A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480060987.4A 2013-10-03 2014-10-02 用于预防或治疗系统性红斑狼疮和/或狼疮性肾炎的方法 Pending CN105705149A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361886403P 2013-10-03 2013-10-03
US61/886,403 2013-10-03
PCT/US2014/058738 WO2015051067A1 (en) 2013-10-03 2014-10-02 Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis

Publications (1)

Publication Number Publication Date
CN105705149A true CN105705149A (zh) 2016-06-22

Family

ID=51842818

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480060987.4A Pending CN105705149A (zh) 2013-10-03 2014-10-02 用于预防或治疗系统性红斑狼疮和/或狼疮性肾炎的方法

Country Status (10)

Country Link
US (2) US20160250238A1 (enExample)
EP (1) EP3052105A1 (enExample)
JP (1) JP2016531886A (enExample)
KR (1) KR20160058886A (enExample)
CN (1) CN105705149A (enExample)
BR (1) BR112016007237A2 (enExample)
CA (1) CA2925935A1 (enExample)
EA (1) EA201690686A1 (enExample)
MX (1) MX2016003979A (enExample)
WO (1) WO2015051067A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515578A (zh) * 2020-05-07 2022-12-23 诺罗瑞韦有限公司 用于治疗抑郁症的环丝氨酸和己酮可可碱联合疗法
CN121041156A (zh) * 2025-08-27 2025-12-02 复皙药业(上海)有限公司 含有替普瑞酮的具有祛红功效的膏霜及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020000092A1 (en) * 2018-06-27 2020-01-02 Algernon Pharmaceuticals Inc. The use of actarit in the prophylaxis or treatment of renal fibrosis or kidney disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090325903A1 (en) * 2008-06-17 2009-12-31 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
CN101772507A (zh) * 2007-08-06 2010-07-07 米伦纽姆医药公司 蛋白酶体抑制剂
WO2012119056A1 (en) * 2011-03-03 2012-09-07 Cephalon, Inc. Proteasome inhibitor delanzomib for use in the treatment of lupus
WO2012177835A1 (en) * 2011-06-22 2012-12-27 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
CA2435146C (en) 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
TW201103904A (en) 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
AU2011235227B2 (en) 2010-03-31 2016-09-08 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101772507A (zh) * 2007-08-06 2010-07-07 米伦纽姆医药公司 蛋白酶体抑制剂
US20090325903A1 (en) * 2008-06-17 2009-12-31 Millennium Pharmaceuticals, Inc. Boronate ester compounds and pharmaceutical compositions thereof
WO2012119056A1 (en) * 2011-03-03 2012-09-07 Cephalon, Inc. Proteasome inhibitor delanzomib for use in the treatment of lupus
WO2012177835A1 (en) * 2011-06-22 2012-12-27 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALEXEI F. KISSELEV等: "Proteasome Inhibitors: An Expanding Army Attacking a Unique Target", 《CHEM BIOL》 *
H. TRAVIS ICHIKAWA等: "Beneficial Effect of Novel Proteasome Inhibitors in Murine Lupus via Dual Inhibition of Type I Interferon and Autoantibody-Secreting Cells", 《ARTHRITIS & RHEUMATISM》 *
KIRSTEN NEUBERT等: "The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis", 《NATURE MEDICINE》 *
NADINE HAINZ等: "The Proteasome Inhibitor Bortezomib Prevents Lupus Nephritis in the NZB/W F1 Mouse Model by Preservation of Glomerular and Tubulointerstitial Architecture", 《NEPHRON EXP NEPHROL》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515578A (zh) * 2020-05-07 2022-12-23 诺罗瑞韦有限公司 用于治疗抑郁症的环丝氨酸和己酮可可碱联合疗法
CN121041156A (zh) * 2025-08-27 2025-12-02 复皙药业(上海)有限公司 含有替普瑞酮的具有祛红功效的膏霜及其制备方法

Also Published As

Publication number Publication date
CA2925935A1 (en) 2015-04-09
MX2016003979A (es) 2016-06-15
BR112016007237A2 (pt) 2017-09-12
US20180099000A1 (en) 2018-04-12
WO2015051067A1 (en) 2015-04-09
JP2016531886A (ja) 2016-10-13
EP3052105A1 (en) 2016-08-10
KR20160058886A (ko) 2016-05-25
EA201690686A1 (ru) 2016-08-31
US20160250238A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
EP2759533B1 (en) Condensed heterocyclic compound
DK2645993T3 (en) Pharmaceutical cream compositions comprising oxymetazoline
JPWO2007123186A1 (ja) 医薬
KR20180080189A (ko) 이상 염증 반응과 연관된 질환을 치료하기 위한 방법 및 조성물
US20100216871A1 (en) Use of compounds having ccr antagonism
AU2015231278B2 (en) Aripiprazole formulations having increased injection speeds
CA2436739A1 (en) Combination agent
JP6207291B2 (ja) 外用剤用組成物
JP7579281B2 (ja) キナーゼ阻害剤の結晶性塩形態
WO2007132825A1 (ja) 医薬
JP2020502270A (ja) 緑内障を処置するための医薬製剤ならびにそれを製造および使用するための方法
US20180099000A1 (en) Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis
CN103917514B (zh) 治疗包括骨髓增生性肿瘤和慢性骨髓性白血病在内的与转导素β样蛋白1(TBL1)活性相关的疾病和病症的方法
CA2605773C (en) Stable emulsion composition
Shui et al. Jieduquyuziyin prescription suppresses IL-17 production and Th17 activity in MRL/lpr mice by inhibiting expression of Ca2+/calmodulin-dependent protein kinase-4
WO2018148638A1 (en) Pharmaceutical compositions of metap-2 inhibitors
US10738004B2 (en) Cyclic compound
JP2016065023A (ja) 複素環化合物
CN105555294A (zh) 可溶性Fc受体的高度浓缩制剂
JP2016222611A (ja) 外用剤用組成物
JP2004002402A (ja) Ｃｃｒ拮抗作用を有する化合物の用途
KR20190013847A (ko) 불안 장애를 치료하기 위한 (2S)-1-[4-(3,4-디클로로페닐)피페리딘-1-일]-3-[2-(5-메틸-1,3,4-옥사디아졸-2-일)벤조[b]푸란-4-일옥시]프로판-2-올 또는 그의 대사산물
JP2004002370A (ja) 重症セプシス予防治療剤
CA3036349C (en) Cyclic compound having toll-like receptor 4 (tlr4) inhibitory activity
KR20160014598A (ko) 제약 조성물 및 그의 용도, 및 필요시 피임을 위한 상기 제약 조성물의 적용 요법

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160622

WD01 Invention patent application deemed withdrawn after publication